Patrick Campbell

Asundexian failed to prove noninferiority to apixaban for its primary efficacy outcome in the phase 3 OCEANIC-AF trial.

Rahul Aggarwal, MD, discusses the findings of a SCORED analysis examining sotagliflozin's effects based on diabetes duration.

Kenneth Mahaffey, MD, discusses FLOW trial data showing semaglutide improves cardiovascular outcomes in patients with type 2 diabetes, regardless of CKD severity.

RESHAPE-HF2 shows mitral transcatheter edge-to-edge repair (M-TEER) reduces heart failure hospitalizations and improves quality of life vs optimal medical therapy alone.

A single blood test using hsCRP, LDL-C, and Lp(a) levels can predict cardiovascular risk for women up to 30 years, emphasizing personalized care.

Sara Diaz Saravia, MD, discusses a study from ESC Congress 2024 examining the utility of cancer history in women as a predictor of subclinical atherosclerosis.

Deepak Bhatt, MD, MPH, MBA, discusses common pitfalls for clinicians when interpreting trial data based on a presentation he led at ESC Congress 2024.

The STOP-or-NOT trial found similar outcomes for continuation or discontinuation of RAS inhibitors before noncardiac surgery, supporting individualized decision-making.

HELIOS-B trial shows vutrisiran reduces all-cause mortality and CV events in ATTR-CM, with benefits consistent regardless of tafamidis use.

The ABYSS trial suggests no clear benefit of continuing beta-blockers post-MI in patients with preserved LVEF, echoing REDUCE-AMI findings.

Kausik Ray, MD, discusses what trials and new data in lipidology he is most looking forward to from the upcoming ESC Congress.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

Dexcom's Stelo, the first OTC glucose sensor, launches in the US on August 26, 2024, offering 15-day wear and HSA/FSA eligibility for as low as $89.99 per 2-pack.

A subgroup analysis of the SELECT trial confirmed semaglutide 2.4 mg benefits patients with heart failure across ejection fraction spectra, improving MACE and heart failure outcomes.

A study involving 6.2 million patients found smoking increases the risk of developing hidradenitis suppurativa, with quitting smoking significantly reducing this risk.

Cascade testing strategies significantly increased the detection of FH, with direct contact yielding a 16-fold higher testing rate, according to the IMPACT-FH study.

Laurence Sperling, MD, offers perspective on multiple topics within the evolving field of lipid management and dyslipidemia.

On August 19, 2024, Liquidia Corporation announced the FDA's tentative approval of treprostinil inhalation powder for adults with PAH and PH-ILD.

HIIT exercise post-stroke improved aerobic fitness more than MICT, with significant gains in peak VO2 after 12 weeks.

Withdrawal of baricitinib in severe alopecia areata led to hair loss in 80% of patients, highlighting the need for ongoing therapy to maintain regrowth.

Deepak Bhatt, MD, MPH, MBA, discusses 7 trials to watch from hotline or late-breaking sessions at the upcoming European Society of Cardiology Congress 2024.

New study suggests MRI-derived pressure measurements indicate a 5-fold increase in heart failure risk.

Laurence Sperling, MD, provides an overview of the Family Heart Global Summit, including previewing the meeting and discussing where interested attendees can learn more.

Study finds 70% of atopic dermatitis patients using dupilumab continued for up to 5 years, but 23.8% discontinued primarily due to adverse events or ineffectiveness.

On August 07, 2024, Novartis announced the FDA's accelerated approval of iptacopan for reducing proteinuria in primary IgAN based on interim data from APPLAUSE-IgAN.

New study highlights racial disparities in psoriasis management, revealing non-Hispanic Black patients are twice as likely to receive a skin biopsy compared to White counterparts.

On August 6, 2024, the FDA warned against using unapproved inhalant products marketed for alertness and energy, citing reports of adverse events including seizures and fainting.

Brett King, MD, PhD, discusses the LEVEL UP trial and how it represents the field of dermatology's desire to advance care and advocate for new standards of care.

On August 05, 2024, less than a month prior to its presentation at ESC 24, Bayter has announced topline data from the FINEARTS-HF trial indicating finerenone met the primary endpoint.